Precision BioSciences (DTIL)
(Delayed Data from NSDQ)
$8.94 USD
-0.02 (-0.22%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $8.93 -0.01 (-0.11%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth B Momentum A VGM
Balance Sheet
Fiscal Year End for Precision BioSciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 117 | 190 | 144 | 90 | 181 |
Receivables | 1 | 1 | 0 | 10 | 1 |
Notes Receivable | 12 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 7 | 9 | 18 | 6 | 12 |
Total Current Assets | 136 | 199 | 162 | 106 | 194 |
Net Property & Equipment | 6 | 20 | 25 | 35 | 40 |
Investments & Advances | 3 | 5 | 7 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 1 | 2 | 1 | 1 |
Deposits & Other Assets | 5 | 10 | 12 | 2 | 1 |
Total Assets | 160 | 238 | 212 | 150 | 235 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 1 | 1 | 1 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 7 | 9 | 11 | 9 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 39 | 47 | 22 | 31 | 16 |
Total Current Liabilities | 50 | 60 | 36 | 43 | 27 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 73 | 83 | 67 | 54 | 66 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 22 | 2 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 10 | 10 | 10 | 0 | 4 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 141 | 178 | 120 | 106 | 97 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 509 | 490 | 409 | 331 | 316 |
Retained Earnings | -490 | -428 | -317 | -286 | -177 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 1 | 1 | 1 | 1 | 1 |
Total Shareholder's Equity | 19 | 60 | 91 | 44 | 138 |
Total Liabilities & Shareholder's Equity | 160 | 238 | 212 | 150 | 235 |
Total Common Equity | 19 | 60 | 91 | 44 | 138 |
Shares Outstanding | 4.10 | 3.60 | 2.00 | 1.70 | 1.60 |
Book Value Per Share | 4.60 | 16.79 | 45.59 | 26.14 | 86.44 |
Fiscal Year End for Precision BioSciences, Inc falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 124 | 138 | 117 | 122 |
Receivables | NA | 0 | 0 | 1 | 4 |
Notes Receivable | NA | 12 | 12 | 12 | 12 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 8 | 11 | 7 | 8 |
Total Current Assets | NA | 144 | 161 | 136 | 146 |
Net Property & Equipment | NA | 4 | 5 | 6 | 9 |
Investments & Advances | NA | 3 | 3 | 3 | 2 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 1 |
Deposits & Other Assets | NA | 6 | 7 | 5 | 6 |
Total Assets | NA | 166 | 185 | 160 | 164 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 1 | 3 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 4 | 2 | 7 | 5 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 26 | 29 | 39 | 43 |
Total Current Liabilities | NA | 33 | 33 | 50 | 51 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 27 | 75 | 73 | 74 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 32 | 10 | 11 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 91 | 148 | 141 | 135 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 524 | 519 | 509 | 503 |
Retained Earnings | NA | -448 | -481 | -490 | -473 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 1 | 1 | 1 | 1 |
Total Shareholder's Equity | NA | 75 | 37 | 19 | 29 |
Total Liabilities & Shareholder's Equity | NA | 166 | 185 | 160 | 164 |
Total Common Equity | 0 | 75 | 37 | 19 | 29 |
Shares Outstanding | 7.20 | 7.20 | 6.90 | 4.10 | 3.80 |
Book Value Per Share | 0.00 | 10.38 | 5.39 | 4.60 | 7.65 |